ECOLCOVID: Ventilation Associated Pneumonia and Covid-19

Sponsor

Centre Hospitalier Universitaire de Nīmes (Other)

Overall Status

Completed

CT.gov ID

NCT05089968

Collaborator

(none)

268

Enrollment

Location

11.5

Actual Duration (Months)

23.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In December 2019, a new pandemic emerged, the COVID-19 disease caused by a SARS-Cov-2 virus. One of the most common symptoms of COVID-19 is mainly respiratory failure and patients requires assistance by mechanical ventilation. Ventilator-associated pneumonia (VAP) is a risk of this assistance. Since the beginning of the pandemic, Standard of care have evolved with new data. The prevalence of these VAPs seems significantly higher in the population of patients with ARDS COVID-19 (40-50%) and their ecology seems to have evolved over time, particularly in terms of bacterial resistance. Investigators want to describe and compare this evolution of bacterial and fungal ecology as well as identify potential risk factors that may be associated with these changes in ecology during different waves.

Condition or Disease	Intervention/Treatment	Phase
SARS-CoV2 Infection Ventilator Associated Pneumonia Ards COVID-19

Study Design

Study Type:

Observational

Actual Enrollment :

268 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Ventilator-associated Pneumonia Ecology Comparison in a French ICU Center NIMES Between First and Second Wave of COVID-19 : a Retrospective Monocentric Descriptive Study

Actual Study Start Date :

Jan 24, 2020

Actual Primary Completion Date :

Jan 8, 2021

Actual Study Completion Date :

Jan 8, 2021

Arms and Interventions

Arm	Intervention/Treatment
Patient from the first wave of COVID-19 57 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 1st wave from January 24, 2020 to July 10, 2020
Patient from the Second wave of COVID-19 211 Patients hospitalized in intensive care unit for pneumonia related to a Sars-Cov2 infection who required mechanical ventilatory support and developed microbiologically documented ventilator associated pneumonia during the 2nd wave from July 11, 2020 to January 8, 2021

Outcome Measures

Primary Outcome Measures

VAP ecological difference between the first and second waves of COVID [January 2020 to January 2021]
Proportion of patients admitted to critical care with documented multidrug-resistant bacteria (MDR) VAP in Covid-19 wave 1 and 2

Secondary Outcome Measures

proportion of fungal co-infections [January 2020 to January 2021]
Comparison of the proportion of patients with a fungal infection during the 1st and 2nd wave
duration of mechanical ventilation [Day 28]
Number of days under mechanical ventilations
number of days of organ failure [Day 28]
number of days between first organ failure and no organ failure (discharge from intensive care)
Mortality [Day 28]
proportion of patients deceased at day 28
proportion of patients treated with corticosteroid therapy [Day 28]
proportion of patients treated with corticosteroid therapy
probabilistic antibiotic therapy at admission [Day 1]
probabilistic antibiotic therapy prescribed at admission
antiviral treatment [Day 28]
proportion of patients treated with antiviral treatment